Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from ValiRx plc ( (GB:VAL) ) is now available.
ValiRx reported additional annual cost savings of £42,500 through salary reductions and changes to its advisory board structure, while continuing to leverage its collaboration with Dominion Biotech to co-develop and market patient-derived cell models and related programmes. The company also expanded its pipeline by signing a preclinical evaluation agreement with McGill University and IRICoR, progressing a fast-track orphan disease programme, and establishing ValiRx Animal Health Ltd to commercialise oncology assets in the veterinary sector, where it is already engaging specialist clinics and potential funders.
The group advanced its CytoLytix oncolytic peptide with a new in-house formulation supported by data from partners ScreeIn3D and Bioreparia, with a patent filing expected in April 2026, and is working with Cellomatics to develop immune-oncology co-culture models using Inaphaea’s colorectal cancer cells. ValiRx further strengthened its academic network via grant-backed collaborations with the University of Nottingham and the Open University on peptide delivery and prostate cancer targeting technologies, while progressing VAL201 2.0 construct validation and planned patent filings, positioning the company to seek external investment and broaden commercial opportunities across human and veterinary oncology.
The most recent analyst rating on (GB:VAL) stock is a Hold with a £0.38 price target. To see the full list of analyst forecasts on ValiRx plc stock, see the GB:VAL Stock Forecast page.
Spark’s Take on VAL Stock
According to Spark, TipRanks’ AI Analyst, VAL is a Neutral.
ValiRx plc’s overall stock score is primarily impacted by its challenging financial performance, characterized by significant losses and reliance on external financing. The technical analysis suggests a bearish trend, with some potential for upward movement. The valuation is unattractive due to a negative P/E ratio and lack of dividend yield.
To see Spark’s full report on VAL stock, click here.
More about ValiRx plc
ValiRx plc is a UK-based life science company focused on early-stage cancer therapeutics and women’s health, using a translational model to move novel drug candidates from pre-clinical stages towards clinic-ready and investor-ready assets. The group operates via subsidiaries and partnerships, leveraging academic and commercial collaborations to streamline oncology and related drug development, and is listed on London’s AIM market under the ticker VAL.
Average Trading Volume: 6,892,895
Technical Sentiment Signal: Strong Sell
Current Market Cap: £2.3M
For detailed information about VAL stock, go to TipRanks’ Stock Analysis page.